Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
8.32
Oct 26 • 3:59 PM ET Dollar change+0.09 Percentage change(1.09%)
Aftermarket Close
8.32
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
37.86M
Enterprise Value
75.57M
Income
-10.41M
Sales
87.81M
Book/sh
1.63
Cash/sh
1.43
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
339
IPO
Dec 07, 2000
P/E
-
Forward P/E
12.90
PEG
-
P/S
0.43
P/B
5.11
P/C
5.82
P/FCF
-
EV/EBITDA
12.66
EV/Sales
0.86
Quick Ratio
0.98
Current Ratio
1.87
Debt/Eq
5.96
LT Debt/Eq
5.74
Option/Short
No / Yes
EPS (ttm)
-2.32
EPS next Y
0.65
EPS next Q
-0.17
EPS this Y
-90.00%
EPS next Y
269.74%
EPS next 5Y
-
EPS past 3/5Y
-77.14% -44.59%
Sales past 3/5Y
-8.60% -3.25%
EPS Y/Y TTM
82.17%
Sales Y/Y TTM
-1.06%
EPS Q/Q
-24.83%
Sales Q/Q
11.13%
Insider Own
7.15%
Insider Trans
0.00%
Inst Own
41.71%
Inst Trans
3.19%
ROA
-13.32%
ROE
-89.95%
ROIC
-20.81%
Gross Margin
54.35%
Oper. Margin
0.65%
Profit Margin
-11.86%
SMA20
0.76%
SMA50
4.06%
SMA200
30.30%
Trades
Shs Outstand
4.55M
Shs Float
4.23M
52W High
9.40 -11.49%
52W Low
3.95 110.53%
Volatility
3.64% 3.92%
ATR (14)
0.31
RSI (14)
55.32
Beta
1.50
Rel Volume
1.34
Avg Volume
18.15K
Volume
24,347
Perf Week
2.84%
Perf Month
4.52%
Perf Quarter
40.54%
Perf Half Y
21.82%
Perf YTD
24.40%
Perf Year
103.97%
Perf 3Y
-80.79%
Perf 5Y
-88.35%
Perf 10Y
-64.60%
Prev Close
8.23
Price
8.32
Change %
1.09%
Date Action Analyst Rating Change Price Target Change
Apr-09-25Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Mar-10-23Upgrade The Benchmark Company Speculative Buy → Buy $3 → $4
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy
Dec-09-20Initiated Northland Capital Outperform $6
Nov-10-20Initiated KeyBanc Capital Markets Overweight $6
Jul-08-19Downgrade Janney Buy → Neutral $2
Jan-24-18Reiterated Janney Buy $5 → $8
Jan-23-18Reiterated The Benchmark Company Buy $6 → $10
Nov-17-16Initiated Singular Research Buy $5.50
Jul-28-15Initiated The Benchmark Company Buy $8
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frost Mark TChief Financial OfficerMar 16 '26Buy5.005,00025,00017,500Apr 01 09:44 AM
DENELSKY STEPHEN JDirectorMar 17 '26Buy4.8710,00048,70021,000Mar 18 02:13 PM
Snider WilliamDirectorMar 16 '26Buy4.9912,52562,50023,525Mar 18 07:31 AM
Snider WilliamDirectorMar 17 '26Buy4.858,47541,10432,000Mar 18 07:31 AM
Duke John DChief Executive OfficerMar 16 '26Buy5.015,00025,050105,000Mar 17 05:56 PM
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, China, United Kingdom, and Rest of the World. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
PresidentMr. John Duke
CFOMr. Mark T. Frost
Vice President of Global People OperationsMs. Lori Packer
Senior Vice President of CommercialMr. David Panzarella
Corporate ControllerKathryn Flynn